...| | | BENZANILIDE | PRODUCT IDENTIFICATION | CAS NO. | 93-98-1 | | EINECS NO. | 202-292-7 | | FORMULA | C6H5NHCOC6H5 | | MOL WT. | 197.24 | | H.S. CODE | | | SMILES | | | TOXICITY | | | SYNONYMS | N-Phenyl Benzamide; N-Phenylbenzoic acid amide; | Benzanilid (German); Benzanilida (Spanish); Benzanilide (French); N-Benzoylaniline; N-Phenylbenzamide | CLASSIFICATION | | PHYSICAL AND CHEMICAL PROPERTIES | PHYSICAL STATE | white to grey crystals | MELTING POINT | 163 C | BOILING POINT | | SPECIFIC GRAVITY | 1.315 | SOLUBILITY IN WATER | Insoluble (soluble in alcohol) | pH | | VAPOR DENSITY | | AUTOIGNITION | | NFPA RATINGS | Health: 1; Flammability: 0; Reactivity: 0 | REFRACTIVE INDEX | | FLASH POINT | 180 C | STABILITY | Stable under ordinary conditions. | GENERAL DESCRIPTION & APPLICATIONS | Amide is a group of organic chemicals with the general formula RCO-NH2 in which a carbon atom is attached to oxygen in solid bond and also attached to an hydroxyl group, where 'R' groups range from hydrogen to various linear and ring structures or a compound with a metal replacing hydrogen in ammonia such as sodium amide, NaNH2. Amides are divided into subclasses according to the number of substituents on nitrogen. The primary amide is formed from by replacement of the carboxylic hydroxyl group by the NH2, amino group. An example is acetamide (acetic acid + amide). Amide is obtained by reaction of an acid...
Words: 3103 - Pages: 13
...Abstract Gleevec is heralded as a savior drug for cancer research. Created by the rational drug design model, Gleevec targets the tyrosine kinase enzyme in CML patients.[10] By targeting and binding to the active sites of the cancerous cells, Gleevec denaturizes them, preventing the spread of the disease.[10] Gleevec has been FDA approved to be administered to patients diagnosed with chronic myelogenous leukemia and also patients with gastrointestinal stromal tumors.[6] Although, this treatment has also been proved to aid in other fields of medicine, ranging from treating other types of cancers to delaying tumor growth to therapy for diabetes and even to cancer treatment in pets.[5,6,8,9] However, for Gleevec to have been made other cell targeted drugs had to be made before it. And just as those drugs paved the way for Gleevec, Gleevec is paving the way for even more cancer treatments to be made. Introduction and Background The official war on cancer began when President Richard Nixon declared that this was the next big thing in the history of the United States. He compared the battle and potential cure of cancer to the process of landing on the moon. However, the battle against cancer has proved to be much more difficult. But there is progress being made. In 2003, 556,902 people in the United States died from cancer.[11] However, in 2002, 557,271 people in the United States died from cancer.[11] Even though the difference of deaths was not that great, this was still...
Words: 2880 - Pages: 12
...WHO DRUG INFORMATION V O L U M E 10 N U M B E R 4 19 9 6 P R O P O S E D INN LIST 76 INTERNATIONAL NONPROPRIETARY NAMES FOR P H A R M A C E U T I C A L S U B S T A N C E S WORLD HEALTH ORGANIZATION • GENEVA Volume 10, Number 4, 1996 World Health Organization, Geneva WHO Drug Information Contents General Policy Topics Meeting the challenge of biotechnology 175 Regulatory Matters Acellular pertussis vaccine for infants Breath test for Helicobacter pylori Restrictions on use of anorectics Coumarin: regulatory action Laxatives: reclassification of common ingredients Is melatonin a prescription drug? NSAIDS, antimicrobials and angioedema Drug-induced liver disease Fluoxetine and hepatitis Hepatitis B vaccine and musculoskeletal reactions Pyrithyldione-diphenhydramine and agranulocytosis Roxithromycin associated with cardiac arrhythmias 187 187 187 188 189 189 189 189 190 190 190 190 Reports on Individual Drugs Confirmation of increased chloroquine resistance in South Africa Which malaria drug for children? Post-malaria neurological syndrome and mefloquine Driving ability in cancer patients treated with morphine Hormone replacement therapy and venous thromboembolism 177 177 177 178 179 Safety Issues Documentation requirements for approval: safety Drug safety monitoring centres 180 181 Recent Publications WHO Expert Committee on Specifications for Pharmaceutical Preparations: Thirty-fourth report International Nonproprietary...
Words: 17347 - Pages: 70
